Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)

NCT05881265 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT05881265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05881265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2023
Completion date
January 1, 2026
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

apl